Trial Profile
A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions
- Acronyms iGRASP
- 22 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Nov 2015 New trial record